GLP-1 Market
LLY $1415.51 ▲ +0.3% NVO $40.70 ▼ -1.6% PFE $28.98 ▼ -0.8% VKTX $29.74 ▲ +2.6% KLRA $14.34 ▲ +4.7% GPCR $22.32 ▲ +4.3% RHHBY $61.32 ▲ +3.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Levacetylleucine

Company
IntraBio Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 10, 2026

Find a Clinical Trial Near Me

See recruiting studies for Levacetylleucine and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05163288

    A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

    Not yet reported IntraBio Inc 53 participants Est. completion 2030-12 14 sites Stand-alone
    Other conditions: Niemann-Pick Disease, Type C
    View official trial listing →
  • Completed NCT NCT00768287

    Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

    Not yet reported, Not yet reported Medexus Pharma, Inc. 77 participants Est. completion 2016-12 23 sites Stand-alone
    Other conditions: Hemophilia B
    View official trial listing →
  • Terminated NCT NCT01271868

    Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

    Not yet reported Medexus Pharma, Inc. 9 participants Est. completion 2016-12 10 sites Stand-alone
    Other conditions: Hemophilia B
    View official trial listing →
  • Completed NCT NCT01885338

    N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

    Not yet reported VA Greater Los Angeles Healthcare System 26 participants Est. completion 2014-05 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT02048111

    Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

    Not yet reported Cangene Corporation Est. completion 2015-11 2 sites Stand-alone
    Other conditions: Hemophilia B
    View official trial listing →
  • Completed NCT NCT03759639

    N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)

    Not yet reported IntraBio Inc 33 participants Est. completion 2022-11-07 9 sites Stand-alone
    Other conditions: Niemann-Pick Disease, Type C
    View official trial listing →
  • Completed NCT NCT03759665

    N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

    Not yet reported IntraBio Inc 30 participants Est. completion 2023-01-09 8 sites Stand-alone
    Other conditions: GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease
    View official trial listing →
  • Terminated NCT NCT03759678

    N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

    Not yet reported IntraBio Inc 17 participants Est. completion 2025-10-27 4 sites Stand-alone
    Other conditions: Ataxia Telangiectasia
    View official trial listing →
  • Completed NCT NCT03855280

    Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

    Not yet reported Medexus Pharma, Inc. 21 participants Est. completion 2022-07-04 11 sites
    Other conditions: Hemophilia B
    View official trial listing →
  • Terminated NCT NCT04784234

    Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin

    Not yet reported Wills Eye 12 participants Est. completion 2022-10-27 1 site
    Other conditions: Primary Open Angle Glaucoma
    View official trial listing →
  • Active, not recruiting NCT NCT06673056

    A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

    Not yet reported IntraBio Inc 60 participants Est. completion 2028-06-01 11 sites Stand-alone
    Other conditions: Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
    View official trial listing →
  • Active, not recruiting NCT NCT07221292

    Pivotal Study of N-acetyl-L-leucine for CACNA1A

    Not yet reported IntraBio Inc 60 participants Est. completion 2028-12-01 11 sites Stand-alone
    Other conditions: CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
    View official trial listing →
  • Approved For Marketing NCT NCT07380165

    Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)

    IntraBio Inc
    Other conditions: Ataxia-Telangiectasia (A-T)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Levacetylleucine, AQNEURSA, N-Acetyl-L-leucine, IB1001

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.